Early research shows a one-time gene therapy has potential for addressing both the liver and lung disease that patients with ...

What risks does Beam face in its clinical development programs? Beam’s reliance on novel base editing technology introduces inherent risks in its clinical development programs. The long-term ...

Not everyone is convinced. Short-sellers warn that biotech companies like Beam face steep financial challenges. Jim Chanos, known for spotting overvalued stocks, believes ARK often gets caught up ...

A Rotorua company's modified crane became a weapon that changed the life of a teenage contractor, who required major surgery.